AbbVie Inc.（ABBV）股票——这是一门好生意吗？

AbbVie Inc.（ABBV）股票——这是一门好生意吗？ — InspectStocks

Just reported

Q3 2026 results

From AbbVie's results release of 2026年10月30日; its quarterly report has since been filed.

Revenue
Actual
US$17.4B
+10% y/y
+2.4% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$2.37
+17% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$6.27B
+229% y/y
-2.6% q/q
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

The full earnings report →

怎么赚钱

Sales of medicines and therapies100%

各项收入占比是对fiscal year 2025, high confidence的估算，并非来自已提交报告的数字。

竞争对手

卖什么6

Skyrizi
An injectable biologic medicine for autoimmune diseases including psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. In 2026, U.S. and European regulators also approved it for some children with plaque psoriasis.
Rinvoq
A once-daily pill for several inflammatory and autoimmune diseases, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease. European regulators approved it for vitiligo and severe alopecia areata in 2026.
Humira
An injectable biologic medicine used for autoimmune conditions including rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis. It faces competition from biosimilar medicines.

再显示 3 项

Botox Therapeutic and Botox Cosmetic
An injectable medicine used therapeutically for conditions including chronic migraine and muscle disorders; its cosmetic version temporarily reduces the appearance of facial lines.
Vraylar
A prescription medicine used to treat schizophrenia and episodes of bipolar disorder, and alongside other medicine for major depression.
Venclexta
A cancer medicine used for blood cancers including chronic lymphocytic leukemia and acute myeloid leukemia. In 2026, U.S. regulators approved a combination with another cancer medicine for some previously untreated adults with chronic lymphocytic leukemia.

谁在买5

Wholesalers and distributors buy medicines for resale to pharmacies, hospitals and other healthcare providers.
Government agencies and public health programs buy medicines or set coverage and reimbursement terms.
Health insurers and pharmacy benefit managers influence which medicines patients can access and the prices or rebates paid.

再显示 2 项

Hospitals, health facilities, specialty pharmacies and independent pharmacies buy medicines for use or dispensing to patients.
Physicians and other licensed healthcare providers prescribe AbbVie's prescription medicines and can buy some aesthetic products and devices directly.

靠什么支撑，什么会击垮它

业务依赖什么

1AbbVie relies on large wholesale distributors to move its medicines, especially in the United States.
2Some medicines or manufacturing components depend on a limited number of suppliers, and in some cases a single supply source.
3Revenue depends on patents and regulatory exclusivity; Humira already faces biosimilar competition.
4Pricing and patient access depend partly on government reimbursement rules, insurers and pharmacy benefit managers.
5The business depends on discovering, testing and obtaining regulatory approval for new medicines, including products developed with collaborators.

可能出什么问题

1Patent expirations and biosimilar or generic competition can reduce sales. Humira's sales continued to fall amid biosimilar competition in the six months ended June 30, 2026.
2Government price controls, reimbursement limits and pressure from insurers and pharmacy benefit managers can reduce the prices AbbVie receives for its medicines.
3Research and development may not produce medicines that pass clinical trials and regulatory review or attract enough use after approval, leaving gaps as existing products lose exclusivity.

完整财务报表 →

关于AbbVie Inc.

AbbVie researches, tests, makes and sells prescription medicines and some medical devices. Its medicines treat immune diseases, neurological conditions, cancers, migraine, eye diseases and other conditions; it also sells cosmetic injections, fillers and skincare products. It sells mainly through wholesalers and distributors, with some aesthetic products sold directly to licensed health professionals.

总部: North Chicago, Illinois, United States
成立于: 2012 (incorporated; began independent public trading in 2013)
员工人数: Approximately 57,000 (December 31, 2025, high confidence)
上市于: New York Stock Exchange
财年结束: December 31

基于 AbbVie Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。

Just reported

Q3 2026 results

From AbbVie's results release of 2026年10月30日; its quarterly report has since been filed.

Revenue
Actual
US$17.4B
+10% y/y
+2.4% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$2.37
+17% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$6.27B
+229% y/y
-2.6% q/q
Guided
—
No guide given

The full earnings report →

Keep exploring

The themes AbbVie is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The themes it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises